Report Highlights

China Muscle Stimulator Market: Market Overview

China's muscle stimulator market reached USD 1.82 billion in 2024, structured across three distinct demand channels: hospital rehabilitation departments, sports and fitness centres, and the rapidly expanding direct-to-consumer e-commerce segment. Government investment in public rehabilitation infrastructure under the National Health Commission's 14th Five-Year Health Plan (2021–2025) has been the primary structural force shaping the professional segment, while private-sector innovation driven by Shenzhen's electronics manufacturing ecosystem has defined consumer product evolution. The market remains split roughly 55% professional and 45% consumer by revenue, though the consumer segment is growing nearly twice as fast.

Policy has been the dominant shaper of the professional segment, with the National Medical Products Administration (NMPA) device registration system determining which products can enter hospital procurement. China's government-led Group Purchasing Organisation (GPO) system, administered through the National Healthcare Security Administration (NHSA), has increasingly incorporated rehabilitation equipment including muscle stimulators into centralised tender cycles since 2022. This has compressed margins for foreign brands while enabling domestic manufacturers like Shenzhen XFT Electronics and Nanjing Kejian Medical to capture institutional contracts through competitive pricing that foreign players cannot match under GPO bid structures.

Policy-Driven Growth in China's Muscle Stimulator Market

Three specific policy mechanisms are actively driving demand. First, the National Health Commission's Rehabilitation Medicine Service Capacity Building Programme, issued in Circular NHC-2021-No.38, mandated that all tertiary-level hospitals establish dedicated rehabilitation departments with standardised equipment lists by end-2023. Muscle stimulators featuring EMS and TENS modalities are explicitly listed as required equipment, creating a procurement obligation across more than 2,700 tertiary hospitals nationwide. This single mandate translated directly into an estimated RMB 2.1 billion in institutional procurement between 2022 and 2024, with residual purchasing continuing as hospitals upgrade older units to NMPA-certified Class II standards.

Second, China's National Fitness Programme (2021–2025), issued by the State Council in August 2021, allocated RMB 500 million in subsidies to community sports recovery facilities, explicitly including electrotherapy and muscle recovery equipment. Third, the Ministry of Human Resources and Social Security's Work Injury Rehabilitation Guidelines (MOHRSS Circular 2022-No.14) expanded reimbursement eligibility for EMS-based occupational injury rehabilitation under the Work Injury Insurance Fund, covering treatments in certified facilities. This reimbursement expansion directly stimulates demand from over 240 million formally employed workers whose occupational injury treatment now includes muscle stimulation therapies as a reimbursable clinical pathway.

Regulatory Barriers and Compliance Costs

The NMPA administers China's medical device registration framework under the Medical Device Supervision and Administration Regulations (State Council Order No. 739, revised 2021). Muscle stimulators classified as Class II medical devices—covering most clinical EMS and TENS products—require a conformity assessment, clinical evaluation dossier, and registration filing with provincial NMPA bureaus before commercial sale. The full registration timeline for foreign manufacturers ranges from 18 to 30 months, with clinical evaluation requirements under NMPA Order No. 73 (2021) demanding either local clinical trial data or a rigorous equivalence argument against a listed predicate device. Registration fees and third-party testing costs typically total RMB 800,000 to RMB 1.5 million per product line for foreign applicants, creating a substantial barrier that disadvantages smaller international entrants relative to established domestic manufacturers with existing NMPA portfolios.

Local content and procurement rules compound registration barriers for foreign firms. Under NHSA GPO bidding rules implemented in 2022, imported medical devices must demonstrate that no domestically produced equivalent exists—a threshold that NMPA-registered domestic EMS devices now satisfy in most product categories. The National Development and Reform Commission (NDRC) enforces the "Made in China 2025" manufacturing localisation expectations, effectively pressuring multinational companies to establish China-based manufacturing or joint venture structures to remain competitive in hospital tenders. Additionally, the Cybersecurity Law (2017) and Personal Information Protection Law (PIPL, 2021), administered by the Cyberspace Administration of China (CAC), impose data localisation requirements on connected EMS wearables, requiring separate compliance infrastructure for app-connected consumer devices that adds estimated RMB 2–5 million in annual compliance costs per platform.

Policy-Created Opportunities in China

The most significant near-term opportunity arises from the National Health Commission's Healthy China 2030 Action Plan, which targets a 35% reduction in chronic musculoskeletal disease burden by 2030 and explicitly identifies non-pharmacological pain management tools including TENS and EMS as priority intervention modalities. The NHC's community health centre upgrade programme, currently in its third phase of funding allocation for 2024–2026, designates RMB 3.8 billion for primary care equipment procurement, with muscle stimulators qualifying under the chronic pain management equipment category. Manufacturers with NMPA Class II registration and existing GPO listing are positioned to access this procurement cycle directly, with contract values averaging RMB 120,000–300,000 per community health centre installation.

A second opportunity stems from the Ministry of Civil Affairs' elderly care facility upgrade initiative under the 14th Five-Year Plan for the Development of the Elderly Care Services System. This programme requires licensed elderly care facilities receiving government subsidies to equip physiotherapy rooms with approved electrotherapy devices, with RMB 1.2 billion in central government grants allocated specifically for rehabilitation equipment across 15,000 targeted facilities by 2025. Consumer-side opportunity is also growing through the NMPA's pilot regulatory sandbox for digital health devices announced in 2023, which creates an accelerated 9-month review pathway for AI-integrated EMS wearables meeting specific safety thresholds, cutting normal Class II timelines by more than half for qualifying connected muscle stimulator products.

Market at a Glance

Leading Market Participants

• Omron Healthcare
• Shenzhen XFT Electronics
• Nanjing Kejian Medical
• Compex (DJO Global)
• Beurer GmbH
• Shenzhen Bosean Technology
• Ito Co. Ltd.
• BioMedical Life Systems
• Guangzhou Longest Science and Technology
• Shenzhen GoldenHorse Technology

Regulatory and Policy Environment

The primary legislative framework governing muscle stimulators in China is the Medical Device Supervision and Administration Regulations (State Council Order No. 739), revised and effective from June 2021, supplemented by the Medical Device Registration and Filing Management Measures (NMPA Order No. 47, 2021) and the Medical Device Clinical Evaluation Technical Guidelines (NMPA Order No. 73, 2021). The NMPA, operating under the State Administration for Market Regulation (SAMR), is the single regulatory authority for device registration, post-market surveillance, and enforcement. Class II muscle stimulators require provincial-level registration, while any device incorporating drug-device combination features or implantable components escalates to Class III requiring national-level NMPA approval. Annual post-market surveillance reports and adverse event reporting within 30 days are mandatory for all registered Class II devices, with non-compliance triggering suspension of distribution licences under NMPA enforcement protocols.

Compared to regional peers, China's regulatory framework is more stringent than ASEAN markets but broadly comparable to South Korea's MFDS system, though China uniquely couples device registration with procurement access through the NHSA GPO system—a linkage not present in Japan or South Korea. Upcoming regulatory changes include the implementation of the Unique Device Identification (UDI) system Phase III rollout, which extends mandatory UDI labelling to all Class II rehabilitation devices by January 2026 under NMPA Announcement No. 66 (2023). Additionally, the NMPA's planned revision of the Classification Catalogue for Medical Devices in 2025 is expected to reclassify high-output consumer EMS devices from general wellness products into Class II, bringing approximately 200 currently unregistered consumer brands into mandatory compliance scope within a 24-month transition window.

Long-Term Policy Outlook for China's Muscle Stimulator Market

By 2032, the Healthy China 2030 initiative will have fully institutionalised muscle stimulation therapy within primary and community healthcare pathways, effectively making NMPA-registered EMS and TENS devices a standard clinical tool at all three tiers of China's healthcare system. The anticipated revision of the Work Injury Insurance Fund reimbursement schedule, expected during the 15th Five-Year Plan period (2026–2030), will expand coverage to home-based EMS therapy supervised by certified practitioners, opening a RMB 5 billion addressable segment currently served informally. Policy direction under China's broader medical device self-sufficiency agenda, reinforced by the NDRC's Medical Equipment Domestic Substitution Guidance issued in 2022, will continue to favour domestically manufactured devices, driving foreign brands to accelerate local manufacturing joint ventures or risk progressive exclusion from public procurement.

The regulatory environment will tighten further around connected and AI-enabled muscle stimulators as the NMPA finalises its Software as a Medical Device (SaMD) guidance framework, expected in final form by late 2025. This framework will require AI-driven personalised stimulation programmes embedded in consumer wearables to undergo algorithm validation and clinical evidence submission as part of Class II registration, raising compliance investment requirements and consolidating the market around well-capitalised domestic players and multinationals with established local regulatory teams. By 2032, the market is expected to operate under a two-tier structure: a regulated, GPO-linked institutional segment dominated by 6–8 large domestic manufacturers, and a certified consumer segment where connected EMS brands with NMPA and CAC dual-compliance status command premium positioning in the USD 200–600 device price band.